Plain-English translation of NCT05069857 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications — Carrelizumab (an immune-boosting drug) and Apatinib (a blood vessel-blocking drug) — can help shrink oral cancer before surgery. Half of the participants will receive these medications for about 6 weeks before their surgery, while the other half will go straight to surgery. Researchers want to see if this medication approach helps people stay cancer-free longer after treatment.
In earlier research, this medication combination showed promise in shrinking tumors significantly before surgery, especially in patients with specific types of oral cancer cells. This trial will test whether this early treatment benefit translates into better long-term survival for patients.
You likely qualify if…
You likely don't qualify if…
If you are assigned to the treatment group, you will receive intravenous infusions and take oral medication over approximately 6 weeks (three 2-week cycles), then proceed to surgery followed by standard follow-up radiation or chemotherapy. If you are in the control group, you will go directly to surgery and standard follow-up treatment. All participants will be followed over 2 years to track whether their cancer returns and how long they survive cancer-free.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China